RecruitingPhase 2NCT06250959

RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

Studying Precursor B-cell acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chen Suning
Principal Investigator
Jing Lu, MD, MD
Soochow U
Intervention
Blinatumomab Injection [Blincyto](drug)
Enrollment
124 target
Eligibility
15-65 years · All sexes
Timeline
20242026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06250959 on ClinicalTrials.gov

Other trials for Precursor B-cell acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Precursor B-cell acute lymphoblastic leukemia

← Back to all trials